Growth expected to stay stable for IHH Healthcare

Nisha Ramchandani

Nisha Ramchandani

Published Wed, Nov 26, 2014 · 09:50 PM

Singapore

DBS Group Research expects hospital operator IHH Healthcare to continue to post stable growth, fuelled by key markets Singapore and Malaysia, although growth in its Turkey operations could be partially impacted by the weaker Turkish lira.

"We expect growth to remain relatively robust and retain our projected earnings growth of 25 per cent/18 per cent/19 per cent for FY14/FY15/FY16 (respectively), driven by the continued ramp-up of new hospitals, coupled with revenue intensities and price increases," wrote DBS analyst Andy Sim in a report. Gleneagles HK Hospital is also on track for completion by end 2016, with the construction contract having been awarded for HK$2.48 billion (S$416.3 million), he noted.

On Tuesday, the dual-listed healthcare provider reported a 26 per cent year-on-year growth in net profit to RM146.9 million (S$57 million) for the third quarter ended Sept 30, while revenue increased 7 per cent to RM1.78 billion. Revenue was boosted by higher inpatient volumes and average revenue for inpatient admission at existing operations, as well as by contributions from new hospitals.

Core earnings - striping out exceptional items - rose 21 per cent year-on-year to RM162.7 million.

During the quarter under review, Ebitda (defined by IHH as earnings before interest, taxes, depreciation, amortisation, exchange differences & other non-operational items) was up 8 per cent to RM427 million, due partly to improving performance at Mount Elizabeth Novena Hospital. Mt Elizabeth Novena's revenue grew 72 per cent year-on-year to RM95.6 million, while Ebitda more than doubled to RM24.9 million.

Meanwhile, Ebitda for Turkey-based Acibadem declined slightly by 2 per cent to RM89.2 million on the back of the weaker Turkish lira. However, the underlying performance was strong and stripping out currency effects, revenue and Ebitda would have increased 12 per cent and 8 per cent year-on-year.

Noting that the group is not impervious to risk, Mr Sim flagged potential downsides such as the impact from a slowing economy, potentially higher staff costs amid a tight labour market as well as the outbreak of epidemics, which could prompt patients to shelve elective surgery.

DBS Group Research has a price target of RM4.54/S$1.80 for IHH, and a "hold" rating on the counter at RM4.94/S$1.89. IHH is listed both in Malaysia and in Singapore.

Shares in IHH closed at S$1.895 on Wednesday, up half a cent.